DS
ENTA icon

DRW Securities’s Enanta Pharmaceuticals ENTA Stock Holding History

DRW Securities’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,000
Closed -$254K – 114
2014
Q4 		$254K Buy
+5,000
New +$224K 0.03% 97

Other funds holding ENTA

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MVM
McClain Value Management New Canaan, Connecticut $50.9M AUM 16.06% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

DRW Securities's ENTA Position: Q1 2015 in Review

DRW Securities sold out of Enanta Pharmaceuticals (ENTA) in Q1 2015, closing a stake of 5,000 shares — an estimated $254K sold.

DRW Securities first reported a position in ENTA in Q4 2014 and held it in 1 quarter. The position peaked at $254K in Q4 2014. 117 funds tracked by Wall St. Rank hold ENTA as of Q1 2015.

  • DRW Securities reported no remaining Enanta Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • DRW Securities sold 5,000 Enanta Pharmaceuticals shares in Q1 2015, an estimated $254K.
  • DRW Securities first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • DRW Securities's Enanta Pharmaceuticals position peaked at $254K in Q4 2014.
  • 117 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2015.

Based on DRW Securities's 13F filing for Q1 2015, filed 15 May 2015.